You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameButabarbital
Accession NumberDB00237  (APRD00752)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionButabarbital (trade name Butisol) is a prescription barbiturate sleep aid. Butabarbital has a particularly fast onset of effects and short duration of action compared to other barbiturates, which makes it useful for certain applications such as treating severe insomnia and relieving anxiety before surgical procedures; however it is also relatively dangerous particularly when combined with alcohol, and so is now rarely used, although it is still prescribed in some Eastern European and South American countries. Its short duration of action gives butabarbital a high abuse potential, comparable to secobarbital. [Wikipedia]
Structure
Thumb
Synonyms
5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-(1-methylpropyl)barbituric acid
5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Sec-butyl-5-ethylbarbituric acid
5-Sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
Butabarbital
Butisol
Secbutabarbital
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Butisol Sodiumtablet30 mg/1oralMeda Pharmaceuticals Inc.1939-08-01Not applicableUs
Butisol Sodium Tab 100mgtablet100 mgoralCarter Horner Corp.1982-12-312001-01-02Canada
Butisol Sodium Tab 15mgtablet15 mgoralCarter Horner Corp.1982-12-312001-01-02Canada
Butisol Sodium Tab 30mgtablet30 mgoralCarter Horner Corp.1982-12-312001-01-02Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ButalanNot Available
ButisolNot Available
Sarisol No. 2Not Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Butabarbital Sodium
Thumb
  • InChI Key: QORQZMBCPRBCAB-UHFFFAOYNA-M
  • Monoisotopic Mass: 234.098037031
  • Average Mass: 234.2275
DBSALT000312
Categories
UNIIP0078O25A9
CAS number125-40-6
WeightAverage: 212.2456
Monoisotopic: 212.116092388
Chemical FormulaC10H16N2O3
InChI KeyInChIKey=ZRIHAIZYIMGOAB-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
IUPAC Name
5-(butan-2-yl)-5-ethyl-1,3-diazinane-2,4,6-trione
SMILES
CCC(C)C1(CC)C(=O)NC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor short-term treatment of insomnia and anxiety disorders
PharmacodynamicsButabarbital, a barbiturate, is used for the treatment of short term insomnia. It belongs to a group of medicines called central nervous system (CNS) depressants that induce drowsiness and relieve tension or nervousness. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Mechanism of actionButabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationBarbiturates are metabolized primarily by the hepatic microsomal enzyme system, and most metabolic products are excreted in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicitySigns of overdose include confusion (severe), decrease in or loss of reflexes, drowsiness (severe), fever, irritability (continuing), low body temperature, poor judgment, shortness of breath or slow or troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness (severe).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9324
Blood Brain Barrier+0.9782
Caco-2 permeable-0.6013
P-glycoprotein substrateSubstrate0.5938
P-glycoprotein inhibitor INon-inhibitor0.617
P-glycoprotein inhibitor IINon-inhibitor0.961
Renal organic cation transporterNon-inhibitor0.9465
CYP450 2C9 substrateNon-substrate0.7719
CYP450 2D6 substrateNon-substrate0.9014
CYP450 3A4 substrateNon-substrate0.7098
CYP450 1A2 substrateNon-inhibitor0.8775
CYP450 2C9 inhibitorNon-inhibitor0.821
CYP450 2D6 inhibitorNon-inhibitor0.933
CYP450 2C19 inhibitorNon-inhibitor0.7828
CYP450 3A4 inhibitorNon-inhibitor0.9203
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9458
Ames testNon AMES toxic0.6458
CarcinogenicityNon-carcinogens0.8533
BiodegradationNot ready biodegradable0.9759
Rat acute toxicity3.6803 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.99
hERG inhibition (predictor II)Non-inhibitor0.9233
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Alpharma us pharmaceuticals division
  • Wockhardt eu operations (swiss) ag
  • Lannett co inc
  • Meda pharmaceuticals inc
  • Halsey drug co inc
  • Cm bundy co
  • Sandoz inc
  • Solvay pharmaceuticals
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Whiteworth towne paulsen inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Marshall pharmacal corp
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral30 mg/1
Tabletoral100 mg
Tabletoral15 mg
Tabletoral30 mg
Prices
Unit descriptionCostUnit
Butisol sodium 50 mg tablet2.46USD tablet
Butisol sodium 30 mg tablet1.89USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point166.5 °CPhysProp
water solubility1360 mg/LNot Available
logP1.65WONG,O & MCKEOWN,RH (1988)
Predicted Properties
PropertyValueSource
Water Solubility1.39 mg/mLALOGPS
logP1.7ALOGPS
logP1.45ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity53.4 m3·mol-1ChemAxon
Polarizability21.41 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4l-6900000000-6e0cbc3d26c5541ad8ebView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Butabarbital is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alprazolam.
AmisulprideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Azaperone.
AzelastineButabarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Butabarbital.
BaclofenThe risk or severity of adverse effects can be increased when Butabarbital is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Butabarbital is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
BrimonidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bupivacaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Buspirone.
ButacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butorphanol.
CarbamazepineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clozapine.
CocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Codeine.
CyclizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Butabarbital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
DoxylamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Butabarbital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
DroperidolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Butabarbital is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Butabarbital is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Butabarbital.
EntacaponeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Eszopiclone.
EthanolButabarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Butabarbital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butabarbital.
EthosuximideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etomidate.
EtoperidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Butabarbital is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Butabarbital is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
HydroxyzineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Isoflurane.
KetamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butabarbital.
LoxapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Butabarbital is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Butabarbital is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methylphenobarbital.
MetyrosineButabarbital may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Butabarbital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
MirtazapineButabarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butabarbital.
MolindoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
NabiloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nalbuphine.
NitrazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Butabarbital is combined with Opium.
OrphenadrineButabarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butabarbital.
OsanetantThe risk or severity of adverse effects can be increased when Butabarbital is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone.
ParaldehydeButabarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Butabarbital.
ParoxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pomalidomide.
PramipexoleButabarbital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butabarbital.
PrilocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Butabarbital is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butabarbital.
RisperidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Romifidine.
RopiniroleButabarbital may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ropivacaine.
RotigotineButabarbital may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Butabarbital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Butabarbital is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Butabarbital is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Butabarbital.
TetrabenazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrodotoxin.
ThalidomideButabarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butabarbital.
ThiamylalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Butabarbital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Butabarbital is combined with Valproic Acid.
VigabatrinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23